Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 19
- DOI:
- 10.3760/cma.j.issn.0366-6999.20131896
- Key Word:
- acute promyelocytic leukemia;arsenic trioxide;thiol;methylation;gene mutation
Abstract： Objective To summarize limitations involved in arsenic trioxide therapeutic effects in acute promyelocytic leukemia,because current studies show that some individuals of acute promyelocytic leukemia have relatively poor outcomes during treatment with arsenic trioxide.Data sources Most relevant articles were included in the PubMed database between 2000 and 2013 with the keywords "acute promyelocytic leukemia","arsenic trioxide","thiol" or "methylation".In addition,a few older articles were also reviewed.Study selection Data and articles related to arsenic trioxide effect in acute promyelocytic leukemia treatment were selected and reviewed.We developed an overview of limitations associated with arsenic trioxide therapeutic effect.Results This review focuses on the researches about the arsenic trioxide therapeutic effect in acute promyelocytic leukemia and summarizes three mainly limitations which can influence the arsenic trioxide therapeutic effect to different degrees.First,with the combination of arsenic and glutathione the therapeutic effect and cytotoxicity decrease when glutathione concentration increases; second,arsenic methylation,stable arsenic methylation products weaken the apoptosis effect of arsenic trioxide in leukemia cells; third,gene mutations affect the sensitivity of tumor cells to arsenic trioxide and increase the resistance of leukemia cells to arsenic trioxide.Conclusions The chief limitations are listed in the review.If we can exclude all of them,we can obtain a better therapeutic effect of arsenic trioxide in patients with acute promyelocytic leukemia.
- [1]Xi, S.,Zheng, Q.,Zheng, Y.,etc.Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment[J].2013,28(5).
- [2]Noriyoshi, Iriyama,Yuta, Yoshino,Bo, Yuan,etc.Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.[J].2012,5.
- [3]Caron S,Marsh DJ,Eng C,etc.PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.[J].1999,8(2).
- [4]Billi AM,Fala F,Tazzari PL,etc.Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.[J].2005,202(2).
- [5]Noriyuki Suzuki,Hua Naranmandura,Kazuo T.Suzuki.Trivalent Arsenicals Are Bound to Proteins during Reductive Methylation[J].2006,19(8).
- [6]Abraham A,Srivastava A,Desire S,etc.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.[J].2010,28(24).
- [7]Y, Akao,Y, Nakagawa,K, Akiyama.Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro.[J].1999,455(1-2).
- [8]Himeno, S.,Sumi, D..Role of arsenic (+3 oxidation state) methyltransferase in arsenic metabolism and toxicity[J].2012,35(11).
- [9]Jennifer L, Beebe-Dimmer,Priyanka T, Iyer,Jerome O, Nriagu,etc.Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study.[J].2012,11.
- [10]Del-Razo LM,Hamilton GA,Wang C,etc.Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells.[J].2000,74(6).
- [11]Hirano S,Cui X,Hayakawa T,etc.A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19.[J].2005,79(4).
- [12]A, Guerci,J L, Merlin,N, Missoum,etc.Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.[J].1995,85.
- [13]Sumner R,Crawford A,Mucenski M,etc.Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor.[J].2000,19(30).
- [14]Desire S,Srivastava A,Viswabandya A,etc.Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.[J].2006,20(5).
- [15]Nakagawa Y,Akao Y,Yamada H.Arsenic-induced apoptosis in malignant cells in vitro.[J].2000,37(1).
- [16]Tomita,A.,Kiyoi,H.,Naoe,T..Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia[J].2013,97(6).
- [17]Vahter M.Mechanisms of arsenic biotransformation.[J].2002,181/182(0).
- [18]K, Kitamura,Y, Minami,K, Yamamoto,etc.Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.[J].2000,14(10).
- [19]Weinfeld M,Charoensuk V,Gati WP.Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells.[J].2009,239(1).
- [20]A. Fraternale,A. Tonelli,A. Casabianca,etc.Role of Macrophage Protection in the Development of Murine AIDS[J].1999,21(2).
- [21]Kann S,Shertzer HG,Xia Y,etc.Butylhydroquinone protects cells genetically deficient in glutathione biosynthesis from arsenite-induced apoptosis without significantly changing their prooxidant status.[J].2005,87(2).
- [22]Hugues de Thé,Morgane Le Bras,Valérie Lallemand-Breitenbach.The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.[J].2012,198(1).
- [23]Himeno S,Sakurai T,Qu W,etc.Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells.[J].2006,91(1).
- [24]Fornecker,L.-M.,Goullé,J.-P.,DeCamaret,B.M.,etc.Mitochondrial myopathy caused by arsenic trioxide therapy[J].2012,119(18).